NCT05660967 (EPCORE DLBCL-3) is a Phase 2 clinical trial of Epcoritamab in Diffuse Large B-Cell Lymphoma, sponsored by Genmab.

Who is sponsoring NCT05660967?

NCT05660967 is sponsored by Genmab.

What drugs are being tested in NCT05660967?

Interventions in NCT05660967: Epcoritamab, Lenalidomide.

What condition does NCT05660967 study?

NCT05660967 studies Diffuse Large B-Cell Lymphoma.

Is NCT05660967 still recruiting?

NCT05660967 is currently active, enrolled. Last updated 8 April 2026.

Last reviewed 2026-04-08 · How we verify

NCT05660967: EPCORE DLBCL-3

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Subcutaneous Epcoritamab With or Without Lenalidomide as First Line Therapy for Diffuse Large B-Cell Lymphoma

Active, enrolled Phase 2 Last updated 8 April 2026

What this trial tests

Phase 2 trial testing Epcoritamab in Diffuse Large B-Cell Lymphoma in 111 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline

6 March 2023

Primary endpoint
14 June 2026

28 June 2026

Quick facts

Lead sponsor	Genmab
Phase	Phase 2
Status	Active, enrolled
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	111
Start date	6 March 2023
Primary completion	14 June 2026
Estimated completion	28 June 2026
Sites	74 locations across France, Italy, Japan, Belgium, Austria, United Kingdom, Germany, Poland

Drugs / interventions tested

Epcoritamab (EPCORITAMAB) — full drug profile →
Lenalidomide — full drug profile →

Conditions studied

Diffuse Large B-Cell Lymphoma — all drugs for Diffuse Large B-Cell Lymphoma →

Sponsor

Genmab — full company profile →

Who can join

75 and older, any sex, with Diffuse Large B-Cell Lymphoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of the study is to examine efficacy and safety of epcoritamab with and without lenalidomide in newly diagnosed elderly patients with Diffuse Large B-Cell Lymphoma (DLBCL) who cannot tolerate anthracycline therapy. Epcoritamab (also known as EPKINLY™, GEN3013 and DuoBody®-CD3xCD20) is an antibody that has already been tested in several clinical studies. All patients will receive active treatment. There is an equal chance of receiving epcoritamab or epcoritamab plus lenalidomide.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Antibodies to watch in 2024.
Crescioli S, Kaplon H, Chenoweth A, Wang L, et al · · 2024 · cited 122× · PMID 38178784 · DOI 10.1080/19420862.2023.2297450
New treatment options in elderly patients with Diffuse Large B-cell Lymphoma.
Arcari A, Cavallo F, Puccini B, Vallisa D. · · 2023 · cited 11× · PMID 37465115 · DOI 10.3389/fonc.2023.1214026
The Evolving Role of Bispecific Antibodies in Diffuse Large B-Cell Lymphoma.
Saleh K, Khoury R, Khalife N, Chahine C, et al · · 2024 · cited 8× · PMID 39063920 · DOI 10.3390/jpm14070666
Changing Trends in B-Cell Non-Hodgkin Lymphoma Treatment: The Role of Novel Monoclonal Antibodies in Clinical Practice.
Tavarozzi R, Zacchi G, Pietrasanta D, Catania G, et al · · 2023 · cited 7× · PMID 38001657 · DOI 10.3390/cancers15225397
Redefining Precision Management of r/r Large B-Cell Lymphoma: Novel Antibodies Take on CART and BMT in the Quest for Future Treatment Strategies.
Dada R. · · 2023 · cited 7× · PMID 37508523 · DOI 10.3390/cells12141858
The Development and Application of Bispecific Antibodies in B-Cell Non-Hodgkin Lymphoma.
Sun L, Romancik JT. · · 2025 · cited 5× · PMID 39997328 · DOI 10.3390/jpm15020051
Bispecific Antibodies for Lymphoid Malignancy Treatment.
Bisio M, Legato L, Fasano F, Benevolo Savelli C, et al · · 2024 · cited 4× · PMID 39796723 · DOI 10.3390/cancers17010094
Bispecific Antibodies and Antibody-Drug Conjugates in Relapsed/Refractory Aggressive Non-Hodgkin Lymphoma, Focusing on Diffuse Large B-Cell Lymphoma.
Caserta S, Campo C, Cancemi G, Neri S, et al · · 2025 · cited 3× · PMID 40805178 · DOI 10.3390/cancers17152479

Verify or expand the search:

Other trials of Epcoritamab

Trials testing the same drug.

NCT07365306 — Epcoritamab, Rituximab, Gemcitabine and Oxaliplatin (R-GemOx) as Salvage Therapy Before Autologous Stem Cell Transplant · Phase 2 · not yet recruiting
NCT07218510 — Venetoclax and Obinutuzumab Followed by Epcoritamab for the Treatment of Untreated Chronic Lymphocytic Leukemia and Smal · Phase 2 · recruiting
NCT06919939 — Epcoritamab in Combination With Loncastuximab Tesirine in Relapsed/Refractory Large B-cell Lymphoma · Phase 2 · recruiting
NCT07097363 — Epcoritamab With Dose Adjusted Etoposide, Cyclophosphamide, Vincristine, Doxorubicin, Prednisone and Rituximab (EPOCH-R) · Phase 2 · recruiting
NCT06796998 — Epcoritamab in Patients With Newly Diagnosed Marginal Zone Lymphoma (MZL) · Phase 2 · recruiting

Other recruiting trials for Diffuse Large B-Cell Lymphoma

Currently open trials in the same condition.

NCT06863402 — Nemtabrutinib and Pembrolizumab for the Treatment of Richter Transformation, Diffuse Large B-cell Lymphoma Subtype · Phase 2 · recruiting
NCT07200375 — An Observational Study of Glofitamab in Chinese Adult Participants With 2L Diffuse Large B-Cell Lymphoma · recruiting
NCT07070648 — Study on Predicting Response to Standard First-Line Treatment in Diffuse Large B-Cell Lymphoma (DLBCL) Patients Using ct · recruiting
NCT07001540 — Evaluation of the Efficacy and Safety of Polatuzumab Vedotin Combined With Rituximab, Gemcitabine, and Oxaliplatin (Pola · Phase 2 · recruiting
NCT06803693 — Efficacy and Safety of Pola-RCHP-X vs Pola-RCHP in Untreated DLBCL · Phase 2 · recruiting

Other Genmab trials

Trials by the same sponsor.

NCT07416123 — A Study of GEN1106 in Participants With Solid Tumors · Phase 1 · recruiting
NCT07384715 — First-in-human (FIH) Trial of GEN3018 in Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML) or Higher-risk Myelod · Phase 1 · recruiting
NCT07288177 — Study to Assess the Efficacy and Safety of Rina-S in Participants With Non-small Cell Lung Cancer · Phase 2 · recruiting
NCT06984328 — Study of the Effectiveness and Safety of Acasunlimab Alone and With Pembrolizumab to Treat Advanced Melanoma of the Skin · Phase 2 · active not recruiting
NCT06771921 — A First-in-Human Trial of Safety and Efficacy of GEN1078 in Participants With Solid Tumors · Phase 1, PHASE2 · terminated

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05660967 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Genmab
Last refreshed: 8 April 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05660967.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing